Validated LC-MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients.

A simple and sensitive LC-MS/MS method was established to quantify total and free mycophenolic acid plasma concentrations during immunosuppressive medication for pediatric renal transplantation. The chromatographic separation was performed with the Hypersil GOLD C18 column, using a mobile phase consisting of 0.1 % formic acid in water and acetonitrile (60:40, v/v) at an isocratic flow rate of 0.4 mL/min. Agilent 6420 triple quadrupole mass spectrometer was operated via a positive electrospray ionization interface using the transitions m/z 321.14→206.9 for MPA and m/z 324.15→209.9 for MPA-d3 (internal standard). The linearity was between 0.1 to 50 μg/mL for tMPA and 0.0025 to 0.5 μg/mL for fMPA. The within-run and between-run precision were all <5% and accuracy was within 96.23%-107.63%. The validated method was successfully applied to the pharmacokinetic study in 28 pediatric renal recipients. The mean free fraction of MPA in our patients was 0.89% (ranging from 0.62% to 1.25%) and albumin level plays a major role in the variability of free fraction of MPA, thus, in pediatric patients with hypoproteinemia, close free drug monitoring and dose adjustments should be considered to prevent toxicity.

[1]  L. Renders,et al.  Simultaneous Determination of Protein-Unbound Cyclosporine A and Mycophenolic Acid in Kidney Transplant Patients Using Liquid Chromatography–Tandem Mass Spectrometry , 2017, Therapeutic drug monitoring.

[2]  P. Kunicki,et al.  Free mycophenolic acid determination in human plasma ultrafiltrate by a validated liquid chromatography-tandem mass spectrometry method. , 2017, Biomedical chromatography : BMC.

[3]  I. Yano,et al.  Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. , 2015, Drug metabolism and pharmacokinetics.

[4]  S. Masuda,et al.  Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. , 2015, Biomedical chromatography : BMC.

[5]  P. Kunicki,et al.  A Comparison of the Immunochemical Methods, PETINIA and EMIT, With That of HPLC-UV for the Routine Monitoring of Mycophenolic Acid in Heart Transplant Patients , 2015, Therapeutic drug monitoring.

[6]  A. Vinks,et al.  Effects of Unbound Mycophenolic Acid on Inosine Monophosphate Dehydrogenase Inhibition in Pediatric Kidney Transplant Patients , 2014, Therapeutic drug monitoring.

[7]  M. Pirmohamed,et al.  Paediatric use of mycophenolate mofetil , 2013, British journal of clinical pharmacology.

[8]  C. Guillemette,et al.  A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  P. Marquet,et al.  Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. , 2011, Transplantation reviews.

[10]  L. Weber,et al.  Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. , 2011, Transplantation reviews.

[11]  A. Domínguez-Gil,et al.  Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma. , 2011, Clinical biochemistry.

[12]  K. Heinig,et al.  Determination of mycophenolic acid and its phenyl glucuronide in human plasma, ultrafiltrate, blood, DBS and dried plasma spots. , 2010, Bioanalysis.

[13]  B. Tönshoff,et al.  Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[14]  M. L. Howard,et al.  Plasma protein binding in drug discovery and development. , 2010, Combinatorial chemistry & high throughput screening.

[15]  L. Shaw,et al.  High-Performance Liquid Chromatography-Mass Spectroscopy/Mass Spectroscopy Method for Simultaneous Quantification of Total or Free Fraction of Mycophenolic Acid and its Glucuronide Metabolites , 2009, Therapeutic drug monitoring.

[16]  Yu Fan,et al.  Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. , 2009, Journal of pharmaceutical and biomedical analysis.

[17]  L. Shaw,et al.  Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients , 2009, Clinical pharmacokinetics.

[18]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  C. Guillemette,et al.  Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  Jiayin Huang,et al.  Prediction of Unbound Mycophenolic Acid Concentrations in Patients After Hematopoietic Cell Transplantation , 2007, Therapeutic drug monitoring.

[21]  M. Pescovitz,et al.  Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. , 2006, Journal of the American Society of Nephrology : JASN.

[22]  M. Zhong,et al.  Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  David W. Johnson,et al.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. , 2005, British journal of clinical pharmacology.

[24]  D. Holt,et al.  Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  David W. Johnson,et al.  Free Mycophenolic Acid Should Be Monitored in Renal Transplant Recipients with Hypoalbuminemia , 2004, Therapeutic drug monitoring.

[26]  David W. Johnson,et al.  Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[27]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[28]  L. Shaw,et al.  Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  R. J. Dumont,et al.  Pharmacokinetics and Protein Binding of Mycophenolic Acid in Stable Lung Transplant Recipients , 2002, Therapeutic drug monitoring.

[30]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[31]  L. Weber,et al.  The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. , 2002, Journal of the American Society of Nephrology : JASN.

[32]  S. Tett,et al.  Quantification of free mycophenolic acid by high-performance liquid chromatography-atmospheric pressure chemical ionisation tandem mass spectrometry. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[33]  L. Weber,et al.  Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. , 1998, Journal of the American Society of Nephrology : JASN.

[34]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[35]  S. Swan,et al.  The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function , 1998, Clinical pharmacology and therapeutics.

[36]  L. Shaw,et al.  Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. , 1995, Clinical chemistry.

[37]  T. Franklin,et al.  The inhibition of nucleic acid synthesis by mycophenolic acid. , 1969, The Biochemical journal.

[38]  A. Dasgupta Therapeutic Drug Monitoring of Mycophenolic Acid. , 2016, Advances in clinical chemistry.

[39]  Peter Shaw,et al.  HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. , 2009, Biomedical chromatography : BMC.

[40]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.

[41]  V. Armstrong,et al.  Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. , 2004, Clinical chemistry.